Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls
중증 COVID-19에서의 토실리주맙 치료: 대조 대조군을 사용한 다기관 후향적 연구
Multicenter Study
[키워드] Activation
acute respiratory distress
acute respiratory distress syndrome
Analysis
anti-IL-6R
approach
ARDS
Arm
ARMS
carried
case-control study
collected
Control
coronavirus
coronavirus disease
COVID-19
criteria
Critical
cytokine
Cytokine storm
death
develop
distress
effective
Efficacy
evaluate
feature
ferritin
Gender
hospitalized COVID-19 patients
IL-6
in some
interleukin
interleukin-6
Interleukin-6 (IL-6)
intubation
logistic regression models
Macrophage
macrophage activation syndrome
multicenter
Multiple
no significant difference
outcome
parameters
Patient
patients
Pneumonia
Primary outcome
procalcitonin
progression
provided
reduced
reduction in
Regression model
reported
respiratory distress
Respiratory distress syndrome
retrospective
retrospective cohort
Retrospective study
SAS
severe disease
shown
significantly
Standard of care
study population
subset
syndrome
Tocilizumab
Treatment
was reduced
was used
[DOI] 10.1007/s00296-021-04965-6 PMC 바로가기 [Article Type] Multicenter Study
[DOI] 10.1007/s00296-021-04965-6 PMC 바로가기 [Article Type] Multicenter Study